Pharmaron Beijing Co Ltd

300759.SZ · Health Technology · Medical Specialties · CN

19,481 employees · pharmaron.cn

About

Pharmaron Beijing Co Ltd generates revenue through four business segments. The Laboratory Services segment offers laboratory chemistry, drug metabolism, pharmacokinetics, absorption, distribution, metabolism, and excretion testing, biology, safety assessment, and discovery of biological agents. The CMC Service segment provides process development, preform production, and analysis for drug manufacturing. The Clinical Development Service segment delivers clinical research, on-site management organization, regulatory biological analysis, and radioactive labeling scientific services. The Biologics and CGT Services segment focuses on macromolecular drug discovery, development, and production, alongside cell gene therapy method development. These services are primarily purchased by pharmaceutical companies and biotechnology firms engaged in drug discovery and development processes.

Annual results

Reported figures, CNY · revenue up 14.8% in 2025

YearRevenueNet incomeNet marginFree cash flow
202514.1B1.7B11.8%—
202412.3B1.8B14.6%—
202311.5B1.6B13.9%—
202210.3B1.4B13.4%—
20217.4B1.7B22.3%—

Dividends per share

2026 0.20 CNY2025 0.20 CNY2024 0.20 CNY2023 0.30 CNY2022 0.30 CNY

300759.SZ in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Pharmaron Beijing Co Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Pharmaron Beijing Co Ltd (300759.SZ) — company profile and financials · MarketPulse